Excessive production of renal reactive oxygen species (ROS) play a major role in diabetic kidney disease (DKD). Here, we provide key novel findings demonstrating the predominant pathological role of the prooxidant enzyme NADPH oxidase-NOX5 in DKD, independent of the previously characterised NOX4 pathway. In diabetic patients, we found increased expression of renal NOX5 in association with enhanced ROS formation and upregulation of ROS-sensitive factors EGR-1 (early growth response 1), PKC-α (protein kinase C- α) and a key metabolic gene involved in redox balance, TXNIP (thioredoxin-interacting protein). In preclinical models of DKD, overexpression of NOX5 in Nox4 deficient mice enhances kidney damage by increasing albuminuria and augmenting renal fibrosis and inflammation via enhanced ROS formation and the modulation of EGR1, TXNIP, ERK1/2, PKC-α and PKC-ε. In addition, the only first in class NOX inhibitor, GKT137831 appears to be ineffective in the presence of NOX5 expression in diabetes. In vitro, silencing of NOX5 in human mesangial cells attenuated high glucose induced upregulation of EGR1, PKC-α, and TXNIP as well as markers of inflammation (TLR4 and MCP-1) and fibrosis (CTGF and collagens I and III) via reduction in ROS formation. Collectively, these findings identify NOX5 as a superior target in human DKD compared to other NOX isoforms such as NOX4 which may have been overinterpreted in previous rodent studies.
Vascular endothelial growth factor receptor‐3 (VEGFR3) signalling promotes lymphangiogenesis. While there are many reported mechanisms of VEGFR3 activation, there is little understanding of how VEGFR3 signalling is attenuated to prevent lymphatic vascular overgrowth and ensure proper lymph vessel development. Here, we show that endothelial cell‐specific depletion of integrin‐linked kinase (ILK) in mouse embryos hyper‐activates VEGFR3 signalling and leads to overgrowth of the jugular lymph sacs/primordial thoracic ducts, oedema and embryonic lethality. Lymphatic endothelial cell (LEC)‐specific deletion of Ilk in adult mice initiates lymphatic vascular expansion in different organs, including cornea, skin and myocardium. Knockdown of ILK in human LECs triggers VEGFR3 tyrosine phosphorylation and proliferation. ILK is further found to impede interactions between VEGFR3 and β1 integrin in vitro and in vivo, and endothelial cell‐specific deletion of an Itgb1 allele rescues the excessive lymphatic vascular growth observed upon ILK depletion. Finally, mechanical stimulation disrupts the assembly of ILK and β1 integrin, releasing the integrin to enable its interaction with VEGFR3. Our data suggest that ILK facilitates mechanically regulated VEGFR3 signalling via controlling its interaction with β1 integrin and thus ensures proper development of lymphatic vessels.
Context
While inflammation has been associated with kidney function in long-standing diabetes, its possible association in newly-diagnosed diabetes is unknown.
Objective
To investigate cross-sectional and prospective associations between biomarkers of inflammation and kidney function in recent-onset diabetes.
Methods
The study included individuals with type 1 and type 2 diabetes with known diabetes duration of &1 year from the German Diabetes Study (GDS). Baseline serum concentrations of 74 biomarkers were measured using proximity extension assay technology and their associations with estimated glomerular filtration rate (eGFR) and kidney function decline over 5 years were tested using multiple linear and logistic regression analysis.
Results
The cross-sectional analysis included 165 individuals with type 1 diabetes and 291 with type 2 diabetes. Baseline eGFR was higher in type 1 compared to type 2 diabetes (102±5 vs. 90±6 mL/min/1.73 m 2; p&0.0001). After full adjustment for covariates and multiple testing, 7 biomarkers were associated with lower baseline eGFR in type 1 diabetes and 24 were associated with lower baseline eGFR in type 2 diabetes. Among these biomarkers, 6 biomarkers (CD5, CCL23, CST5, IL-10RB, PD-L1, TNFRSF9) were inversely associated with eGFR in both diabetes types. The prospective analysis did not detect associations between inflammatory biomarkers and kidney function decline. No evidence of an interaction between diabetes type and inflammatory biomarkers was found.
Conclusion
Several biomarkers of inflammation associate with lower baseline eGFR in recent-onset type 1 and type 2 diabetes, but do not associate with kidney function loss during the first 5 years after the diagnosis of diabetes.
Excessive production of renal
reactive oxygen species (ROS) play a major role in diabetic kidney disease
(DKD). Here, we provide key novel findings demonstrating the predominant pathological role of the prooxidant
enzyme NADPH oxidase-NOX5 in DKD, independent of the previously
characterised NOX4 pathway.
In diabetic patients, we found increased expression of renal NOX5 in
association with enhanced ROS formation and upregulation of ROS-sensitive
factors EGR-1 (early
growth response 1), PKC-α (protein kinase C- α) and a key metabolic gene
involved in redox balance, TXNIP (thioredoxin-interacting
protein). In preclinical models
of DKD, overexpression of <i>NOX5</i> in <i>Nox4</i> deficient mice enhances kidney damage by increasing albuminuria and augmenting renal fibrosis
and inflammation via enhanced ROS formation and the modulation of EGR1, TXNIP,
ERK1/2, PKC-α and PKC-ε. In addition, the only first in class NOX inhibitor,
GKT137831 appears to be ineffective in the presence of NOX5 expression in
diabetes. In vitro, silencing of NOX5
in human mesangial cells attenuated high glucose induced upregulation of EGR1, PKC-α,
and TXNIP as well as markers of
inflammation (TLR4 and MCP-1) and fibrosis (CTGF and collagens I and III) via
reduction in ROS formation. Collectively, these findings identify NOX5
as a superior target in human DKD compared to other NOX isoforms such as NOX4 which may have been
overinterpreted in previous rodent studies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.